In ESCC was shown that MEK inhibitors, targeting the RAS-RAF-MEK-MAPK-ELK1 pathway, activate STAT3-mediated signaling, while dual inhibition of the two pathways resulted in decreased cell proliferation [205]. Here, ELK1 is linked to esophageal squamous cell carcinoma.